BioSpace News Archive

Breakthrough Discoveries on Novel Features of Omicron Variant and An Anti-Omicron Antibody JMB2002

Joint research results from Biologics of Jemincare and Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences (CAS) confirmed that JMB2002, an anti-SARS-CoV-2 neutralizing antibody (NAb) discovered by Biologics of Jemincare is still effective against Omicron variant of SARS-CoV-2.

January 3, 2022
·
3 min read
Drug Development

AKESO’S CADONILIMAB (PD-1/CTLA-4 BI-SPECIFIC ANTIBODY) COMBINED WITH CONCURRENT CHEMORADIOTHERAPY OBTAINED APPROVAL TO INITIATE A PHASE III CLINICAL TRIAL FOR THE TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER

Today, Akeso (09926.HK) announces that Cadonilimab (PD-1/ CTLA-4 bi-specific antibody), combined with concurrent chemoradiotherapy obtained approval from the Center for Drug Evaluation (‘CDE’) of the National Medical Products Administration of the People’s Republic of China (''China’’) to initiate a phase III clinical trial for the treatment of locally advanced cervical cancer.

January 3, 2022
·
2 min read